Wall Street Analyst Raises Eli Lilly Target to $1,400 Following Pipeline Gains

New York, Wednesday, 16 September 2026.
Berenberg upgraded Eli Lilly to a Buy rating, raising its price target to $1,400 after admitting it previously underestimated the pharmaceutical giant’s expanding external pipeline.